Dermatological drugs – new study showing you trends, partnerships, and predicted revenues Where is the market for dermatological drugs heading? What are the commercial prospects for this market? Visiongain’s new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.
Our 310 page report provides 220 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket, regional and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.
Forecasts from 2015-2025 and other analyses show you commercial prospects Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces), company profiles and commercial developments. Read the full transcript of an exclusive expert opinion interview from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales: • Kathleen Deardorff, Chief Operating Officer (COO) at Photocure ASA
You will find prospects for key submarkets In addition to analyses of the overall world market, you will see revenue forecasting of five world-level submarkets to 2025: • Skin infection drugs market forecast 2015-2025 • Dermatitis drugs market forecast 2015-2025 • Acne drugs market forecast 2015-2025 • Psoriasis drugs market forecast 2015-2025 • Other dermatological drugs market forecast 2015-2025
Our investigation shows business research and analysis with individual revenue forecasts and discussions for each submarket.
See revenue forecasts for products How will leading drugs perform to 2025 at world level? Our study forecasts sales of 24 products, including these brands: • Remicade • Humira • Claravis • Epiduo • Bepanthen • Solodyn • Enbrel • Protopic • Cubicin • Canesten
Discover how high revenues can go. You will see what’s happening, understanding trends, challenges and opportunities.
What are the prospects for the leading regions and countries? Our analyses show sustained growth in the dermatological drugs market, particularly in the emerging economies where growing affluence and rising government support will impact the growth of dermatological drugs.
In addition to analyses of the overall world market, you discover individual revenue forecasts for national and regional markets to 2025. Future trends within each region are examined. You will discover individual revenue forecasts for 12 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries. • US • China • Japan • Germany • India • France • UK • Italy • Spain • Brazil • Russia • Mexico • Rest of the World
Our analyses show that emerging economies, particularly in South America and Asia, will continue to achieve high revenue growth to 2025. Various economic, geographical, and regulatory factors globally will influence the market.
Leading companies and potential for market growth Over the last few years, the market for dermatological drugs globally has witnessed a number of strategic acquisitions and restructuring. The global dermatological drugs market will reach $24.5bn in 2015, according to Visiongain’s forecast. Rising demand for dermatological drugs, expanding healthcare coverage, the success of biological drugs, and antibacterial drug resistance will aid in the growth of the overall market to 2025.
Our work shows you what organisations hold greatest potential. See profiles of 6 leading companies, including these: • AbbVie • Galderma • GlaxoSmithKline • Johnson & Johnson • LEO Pharma • Pfizer
A company profile gives you the following information: • Revenue forecast for dermatological drugs from 2015 to 2025 • Recent financial results • Assessment of recent developments – mergers and acquisitions (M&A), and collaborations, including alliances, partnerships, and joint ventures • Discussion of a company's activities and outlook
Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will regulatory changes have?
Research and development activities – assess innovation, trends and possibilities What is happening in the R&D pipeline for dermatological treatments? You see developmental trends, gaining insight into each phase of the dermatology R&D pipeline for: • Acne pipeline drugs • Dermatitis pipeline drugs • Psoriasis pipeline drugs • Skin infections pipeline drugs • Other progress in dermatology
Our study also discusses these agents and technologies, among others: • Photodynamic therapy • Drug delivery • Novel small molecules • Oral drug candidates
What issues will affect the dermatological drugs market? Our new report lets you assess industry trends and outlooks. Our study discusses issues affecting dermatological treatments. You will find discussions, including qualitative analyses: • Pricing and reimbursement pressures created by government cost-cutting initiatives • Patient compliance and the advances in topical drug delivery • A strong R&D pipeline • Personalised dermatology and genomics • Consolidation among players in the market • Patent expiries and generic competition • The changing socio-economic conditions impacting dermatological drug demand • Demographic trends impacting demand for dermatological drugs
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape
How the Dermatological Drugs Market Forecast 2015-2025: Opportunities for Leading Companies report helps you In summary our 310 page report gives you the following knowledge: • Revenues to 2025 for the overall dermatological drugs market – discover the industry’s prospects, finding promising areas for investments and revenues • Revenue forecasts to 2025 for four product categories (therapeutic classes) within dermatological drugs – discover forecasts for Psoriasis drugs, Dermatitis drugs, Acne drugs, Skin infection drugs, and Other dermatological drugs • Revenue forecast to 2025 for 12 leading national markets – US, China, Japan, India, Germany, France, UK, Italy, Spain, Russia, Brazil, Mexico, and Rest of the World • Assess leading companies – hear about the products, results and strategies, including recent activities, future outlook, and dermatological drugs revenue forecast for 6 leading companies, including Pfizer, LEO Pharma, Johnson & Johnson, AbbVie, and GlaxoSmithKline • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market • Opinions from our survey, seeing interviews with industry authorities • IP protection and generic drug competition – see what affects product revenue
You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the dermatological drugs market and the leading companies within it. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Dermatological Drugs: Market Overview 1.2 Global Dermatological Drugs Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered By This Analytical Report 1.6 Who Is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Reports 1.10 About Visiongain
2. An Introduction To Dermatological Drugs 2.1 The Pharmaceutical Industry: A Brief Introduction 2.2 An Introduction To Dermatology 2.2.1 The Structural Lay-out Of The Skin, Hair, And Nails 2.2.2 Hair And Nails 2.2.3 Sweat And Sebaceous Glands 2.2.4 Functions Of The Skin 2.3 Common Skin Diseases 2.4 Acne: The Most Common Skin Disease 2.4.1 Acne: Epidemiology 2.4.2 Acne: Causes And Pathogenesis 2.4.3 Acne: Treatment 2.5 Dermatitis: Inflammation Of The Skin 2.5.1 Atopic Dermatitis 2.5.2 Contact Dermatitis 2.5.3 Seborrhoeic Dermatitis 2.5.4 Nummular Dermatitis 2.5.5 Perioral Dermatitis 2.6 Psoriasis: A Complex Multi-factorial Disease 2.7 Rosacea: Vascular Instability 2.8 Alopecia: Excessive Shedding Of Hair 2.9 Skin Infections: A Serious Healthcare Threat 2.9.1 Bacterial Skin Infections 2.9.2 Fungal Skin Infections 2.9.3 Viral Skin Infections 2.10 Common Skin Treatments 2.10.1 Creams and Semisolid Emulsions 2.10.2 Ointments 2.10.3 Lotions 2.10.4 Solutions 2.10.5 Occlusive Therapy 2.10.6 Cleansing Agents 2.10.7 Powders and Hydrophilic Polymer 2.10.8 Anti-Infective Agents 2.10.9 Anti-Inflammatory Agents 2.11 Phases Of Clinical Trials 2.12 Dermatological Drugs: Market Definition In This Report
3. The Global Dermatological Drugs Market, 2015-2025 3.1 The Global Dermatological Drugs Market: Market Overview 3.2 Categorisation Of The Global Dermatological Drugs Market 3.3 The Global Dermatological Drugs Market In 2014 3.4 The Global Dermatological Drugs Market: Market Forecast 2015-2025 3.5 Dermatological Drugs: Changing Market Shares By Sector 2015-2025
4. The Psoriasis Drugs Market: Market Analysis And Forecast 2015-2025 4.1 Psoriasis Treatments: The Dominance Of Biologics 4.1.1 Leading Products In The Psoriasis Drugs Market, 2014 4.2 Psoriasis: Market Trends And Developments, 2015 4.2.1 Biological Drugs In Psoriasis Treatment: A Brief Overview 4.2.2 Issues Around Patent Protection, The Threat Of Biosimilars And Pricing 4.2.3 The Disadvantages Of Biologics In Psoriasis Treatment 4.3 Psoriasis Drugs: Market Forecast 2015-2025 4.3.1 Psoriasis Drugs: Changing Market Shares By Leading Drugs 2015-2025 4.4 Leading Drugs Used In The Treatment Of Psoriasis 4.5 Humira (adalimumab) - AbbVie 4.5.1 Humira: Historical Sales Analysis, 2010-2014 4.5.2 Humira: Sales Forecast 2015-2025 4.5.3 Future Prospects For Biosimilar Versions Of Humira 4.6 Stelara (ustekinumab) – Johnson & Johnson 4.6.1 Stelara: Historical Sales Analysis, 2010-2014 4.6.2 Stelara: Sales Forecast 2015-2025 4.6.3 Intensifying Competition For Stelara 4.7 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda 4.7.1 Enbrel: Co-Promotions And Marketing Rights 4.7.2 Enbrel: Historical Sales Analysis, 2008-2014 4.7.3 Enbrel: Patent Expiries and Potential Competition, 2015-2025 4.7.4 Enbrel: Sales Forecast 2015-2025 4.7.5 Enbrel Auto-injector Pens: A Driver Of Growth In Recent Years 4.7.6 Competition From Other Drugs 4.7.7 Biosimilar Competition For Enbrel 4.8 Remicade (infliximab) – Johnson & Johnson 4.8.1 Remicade: Historical Sales Analysis, 2010-2014 4.8.2 Remicade: Patent Expiries and Potential Competition, 2015-2025 4.8.3 Remicade: Sales Forecast 2015-2025 4.9 Daivobet (betamethasone/calcipotriene) - LEO Pharma 4.9.1 Daivobet: Sales Forecast 2015-2025 4.9.2 LEO Pharma’s Life Cycle Management Of Daivobet 4.9.3 Daivobet/Dovobet/Taclonex – Generic Competition 4.10 Soriatane (acitretin) – GlaxoSmithKline 4.10.1 Soriatane: Sales Forecast 2015-2025 4.11 Other Psoriasis Drugs 4.11.1 Cimzia (certolizumab) - UCB 4.11.2 Cosentyx (secukinumab) – Novartis 4.11.3 Otezla (apremilast) - Celgene 4.11.4 Sorilux (calcipotriene foam) - GSK 4.11.5 Other Psoriasis Drugs: Sales Forecast 2015-2025 4.12 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis And Forecast 2015-2025 5.1 Skin Infection Drugs: Abundant Growth Opportunities 5.1.1 Leading Products In The Skin Infection Drugs Market, 2014 5.2 Skin Infection Drugs: Market Forecast 2015-2025 5.2.1 Skin Infection Drugs: Changing Market Shares By Leading Drugs 2015-2025 5.3 Leading Drugs Used In The Treatment Of Skin Infections 5.4 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co 5.4.1 Acquisition By Merck & Co 5.4.2 Generic Competition For Cubicin 5.4.3 Cubicin: Sales Forecast 2015-2025 5.4.4 Lifecycle Management Strategies For Cubicin 5.5 Zyvox (linezolid) - Pfizer 5.5.1 Zyvox: Historical Sales Analysis, 2010-2014 5.5.2 Zyvox: Sales Forecast 2015-2025 5.5.3 The Threats To Zyvox Sales From Competing New Drugs 5.6 Valtrex (valaciclovir) - GSK 5.6.1 Valtrex: Historical Sales Analysis, 2010-2014 5.6.2 Valtrex: Sales Forecast 2015-2025 5.7 Canesten (clotrimazole) - Bayer 5.7.1 Canesten: Historical Sales Analysis, 2011-2014 5.7.2 Canesten: Sales Forecast 2015-2025 5.8 Lamisil (terbinafine) - Novartis 5.8.1 Lamisil Patent Expiry 5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems 5.8.3 Lamisil: Sales Forecast 2015-2025 5.9 Bactroban (mupirocin) - GSK 5.9.1 Bactroban: Historical Sales Analysis, 2010-2013 5.9.2 Bactroban: Sales Forecast 2015-2025 5.10 Other Skin Infection Drugs 5.10.1 Dalvance (dalbavancin) - Durata Therapeutics 5.10.2 Jublia (efinaconazole) - Valeant 5.10.3 Kerydin (tavaborole) - Anacor 5.10.4 Sivextro (tedizolid) – Cubist Pharmaceuticals 5.10.5 Zovirax (acyclovir) - Valeant/GSK 5.10.5.1 Valeant Acquires Zovirax In US And Canada 5.10.5.2 Mylan’s Generic Zovirax And Actavis’ Authorised Generic 5.10.6 Other Skin Infection Drugs: Sales Forecast 2015-2025 5.11 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis And Forecast 2015-2025 6.1 Acne Drugs: A Diversified Market 6.1.1 Leading Products In The Acne Drugs Market, 2014 6.2 Acne Drugs Market: Recent Trends and Developments 6.2.1 The Rise Of Combination Therapies In Acne Treatment 6.2.2 Oral Contraceptives In Treating Acne 6.2.3 The Threat Of Generic Competition In The Acne Drugs Market 6.3 Acne Drugs: Market Forecast 2015-2025 6.3.1 Acne Drugs: Changing Market Shares By Leading Drugs 2015-2025 6.4 Leading Drugs In The Acne Drugs Market 6.5 Solodyn (minocycline) - Valeant 6.5.1 Solodyn: Sales Forecast 2015-2025 6.5.2 Antitrust Action Over Solodyn Pay-For-Delay Deals 6.5.3 Impax And Medicis Collaborating On Advanced Solodyn 6.5.4 Medicis And Lupin Settle 6.6 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health 6.6.1 Epiduo: Sales Forecast 2015-2025 6.6.2 Galderma Settlement Agreement Over Generic Epiduo 6.6.3 Paediatric Approval For Epiduo 6.7 Claravis (isotretinoin) - Teva 6.7.1 Claravis: Sales Forecast 2015-2025 6.8 Aczone (dapsone) - Allergan 6.8.1 Aczone: Sales Forecast 2015-2025 6.9 Differin (adapalene) – Galderma/ Nestlé Skin Health 6.9.1 Recent Generic Competition To Differin 6.9.2 Differin: Sales Forecast 2015-2025 6.9.3 Federal Circuit Court Invalidates Differin Patents 6.10 Absorica/Epuris (CIP-isotretinoin) – Cipher/ Sun Pharma 6.10.1 Absorica/Epuris: Sales Forecast 2015-2025 6.11 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International 6.11.1 Valeant’s Patent Settlement With Actavis Over Ziana 6.11.2 Ziana: Sales Forecast 2015-2025 6.12 Doryx (doxycycline) – Actavis/ Mayne Pharma 6.12.1 Lifecycle Management Strategies For Doryx 6.12.2 Divestment Agreement With Mayne Pharma 6.12.3 Generic Competition For Doryx 6.12.4 Doryx: Sales Forecast 2015-2025 6.13 Other Acne Drugs 6.13.1 Acanya (clindamycin/benzoyl peroxide) – Dow / Valeant 6.13.1.1 Acanya: Financial Analysis 6.13.1.2 Actavis Claims First-to-File Exclusivity for its Acanya ANDA 6.13.1.3 Legal Battles Involving Dow/Valeant, Perrigo, And Watson 6.13.2 Amnesteem (isotretinoin) - Mylan 6.13.2.1 Amnesteem: Financial Analysis 6.13.3 Diane (cyproterone/ethinyl estradiol) - Bayer 6.13.4 Duac (clindamycin/benzoyl peroxide) – GlaxoSmithKline 6.13.4.1 Duac: Financial Analysis 6.13.5 Veltin (tretinoin/clindamycin) - GSK 6.13.6 Other Acne Drugs: Sales Forecast 2015-2025 6.14 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis And Forecast 2015-2025 7.1 Dermatitis Drugs: High Generic Penetration 7.1.1 Leading Products In The Dermatitis Drugs Market, 2014 7.2 Dermatitis Drugs: Market Forecast 2015-2025 7.2.1 Dermatitis Drugs: Changing Market Shares By Leading Drugs 2015-2025 7.3 Leading Drugs In The Dermatitis Drugs Market 7.4 Bepanthen (dexpanthenol)/ Bepanthol - Bayer 7.4.1 Bepanthen: Sales Forecast 2015-2025 7.5 Protopic (tacrolimus) - Astellas Pharma/ Roche 7.5.1 Protopic Benefits From Expanded Indication 7.5.2 Generic Competition For Protopic 7.5.3 Protopic: Sales Forecast 2015-2025 7.6 Elidel (pimecrolimus) – Meda Pharma/ Valeant 7.6.1 Elidel: Sales Forecast 2015-2025 7.7 Elocon (mometasone) - Merck & Co 7.7.1 Elocon: Sales Forecast 2015-2025 7.8 Other Dermatitis Drugs: Sales Forecast 2015-2025 7.9 Dermatitis Drugs: Market Outlook
8. Leading National Markets For Dermatological Drugs, 2015-2025 8.1 The Dermatological Drugs Market By Region 8.1.1 The Global Distribution Of Dermatological Drugs In 2014 8.2 Leading National Markets: Forecast 2015-2025 8.2.1 Changing Market Shares By Region, 2015-2025 8.3 Regional Dermatological Drugs Markets: Analysis And Forecasts, 2015-2025 8.4 United States: The Largest Dermatological Drugs Market 8.4.1 The Impact Of An Expanding Medicare Coverage 8.4.2 Legislative Environment Stimulating Biosimilars Market? 8.4.3 US Dermatological Drugs Market: Market Forecast 2015-2025 8.5 The EU5 Markets: Growth Expected In Each Country 8.5.1 EU5 Dermatological Drugs Market: Market Forecast 2015-2025 8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025 8.5.2 Germany 8.5.2.1 German Dermatological Drugs Market: Market Forecast 2015-2025 8.5.3 France 8.5.3.1 French Dermatological Drugs Market Forecast 2015-2025 8.5.4 UK 8.5.4.1 UK Dermatological Drugs Market Forecast 2015-2025 8.5.5 Italy 8.5.5.1 Italian Dermatological Drugs Market Forecast 2015-2025 8.5.6 Spain 8.5.6.1 Spanish Dermatological Drugs Market Forecast 2015-2025 8.6 Japan 8.6.1 The Cost Of Treatment In Japan 8.6.2 Japanese Pharmaceutical Industry Regulatory Reform 8.6.3 Japanese Dermatological Drugs Market Forecast 2015-2025 8.7 China 8.7.1 Expansion Of Healthcare Coverage And Reimbursement In China 8.7.2 Improving Public Perception Of Dermatology In China 8.7.3 Price Controls And The Anhui Model 8.7.4 Chinese Dermatological Drugs Market Forecast 2015-2025 8.8 India 8.8.1 The Effects Of The Drug Prices Control Order Of 2013 8.8.2 India’s Expansion Of Healthcare Provision 8.8.3 Indian Dermatological Drugs Market Forecast 2015-2025 8.9 Brazil 8.9.1 The Growth In Brazil’s Healthcare Landscape 8.9.2 Clearer Access To Medicines In Brazil 8.9.3 Brazilian Dermatological Drugs Market Forecast 2015-2025 8.10 Russia 8.10.1 Pharma2020 Strategy - Healthcare And Industry Reform 8.10.2 Russian Dermatological Drugs Market Forecast 2015-2025 8.11 Mexico 8.11.1 Seguro Popular: Mexican Healthcare Reform 8.11.2 Are Multinationals Waking Up To Mexico’s Potential? 8.11.3 Mexican Dermatological Drugs Market Forecast 2015-2025 8.12 Rest of the World 8.12.1 The Rest of the World Dermatological Drugs Market Forecast 2015-2025
9. Leading Companies In The Dermatological Drugs Market, 2015-2025 9.1 Dermatological Drugs – A Rapidly Consolidating Market 9.2 Galderma (Nestle Skin Health S.A.) 9.2.1 Galderma: Dermatological Drugs Portfolio, 2015 9.2.2 Galderma: Recent Developments 9.2.2.1 Nestlé’s Acquisition Of Galderma 9.2.2.2 Approval Of Soolantra For Rosacea 9.2.2.3 Mirvaso Launched For Rosacea 9.3 Johnson & Johnson 9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2015 9.3.2 Johnson & Johnson Dermatological Drugs Sales Forecast 2015-2025 9.3.3 Johnson And Johnson: Dermatological Drug Development Efforts, 2015 9.4 AbbVie 9.4.1 AbbVie: Dermatological Drugs Portfolio, 2015 9.4.2 AbbVie Dermatological Drugs Sales Forecast 2015-2025 9.4.3 AbbVie: Dermatological Drugs Development Pipeline, 2015 9.4.3.1 BT-061 (tregalizumab) For The Treatment Of Psoriasis 9.5 GlaxoSmithKline (GSK) 9.5.1 GSK: Dermatological Drugs Portfolio, 2015 9.5.2 GlaxoSmithKline (GSK) Dermatological Drugs Sales Forecast 2015-2025 9.5.3 GlaxoSmithKline (GSK): Recent Developments 9.5.3.1 Business Restructuring Arrangements With Novartis 9.5.3.2 Tafinlar and Mekinist Combination Approved by FDA, Withdrawn in EU 9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2015 9.6 Pfizer 9.6.1 Pfizer: Dermatological Drugs Portfolio, 2015 9.6.2 Pfizer Dermatological Drugs Sales Forecast 2015-2025 9.6.3 Pfizer: Dermatological Drugs Development Pipeline, 2015 9.7 LEO Pharma 9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2015 9.7.2 LEO Pharma Dermatological Drugs Sales Forecast 2015-2025
10. Dermatological Drugs: Research And Development Pipeline, 2015-2025 10.1 Innovative Products Currently In Development Will Drive Growth 10.1.1 New Technology In R&D Pipeline Activities 10.1.1.1 Reformulation 10.1.1.2 Combination Treatments 10.1.1.3 New Mechanisms And Drug Delivery Technologies 10.1.1.4 Potential Market Entrants 10.2 Psoriasis Drugs Development Pipeline, 2015 10.2.1 Psoriasis Drugs In Phase 3 Development 10.2.1.1 000-0551 Lotion (halobetasol) - Therapeutics, Inc 10.2.1.2 AMG 827 (brodalumab) - AstraZeneca/ Amgen 10.2.1.3 CF101 (IB-MECA) - Can-Fite BioPharma 10.2.1.4 CNTO 1959 (guselkumab) - MorphoSys/ Janssen 10.2.1.5 LAS41008 (dimethyl fumarate) - Almirall 10.2.1.6 LEO 90100 - LEO Pharma 10.2.1.7 LY2439821 (ixekizumab) - Eli Lilly 10.2.1.8 MK-3222/SCH 900222 (tildrakizumab) - Merck 10.2.1.9 STF 115469 (calcipotriene foam) - GSK 10.2.1.10 Xeljanz (tofacitinib) - Pfizer 10.2.2 Psoriasis Drugs In Phase 2 Development 10.2.2.1 AN2728 (PDE-4 inhibitor) - Anacor Pharmaceuticals 10.2.2.2 CT327 (TrkA inhibitor) - Creabilis Therapeutics 10.2.2.3 ASP015K (JAK inhibitor) – Astellas Pharma 10.2.2.4 Jakavi/Jakafi (ruxolitinib) - Incyte/ Novartis 10.2.2.5 LY3009104 (baricitinib) - Incyte/ Eli Lilly 10.2.2.6 PH-10 (Rose Bengal) - Provectus Biopharmaceuticals 10.2.3 Psoriasis Drugs In Phase 1 And Pre-clinical Development 10.3 Skin Infection Drugs Development Pipeline, 2015 10.3.1 Drugs In Phase 3 Development For Skin Infections 10.3.1.1 Delafloxacin (delafloxacin) - Melinta Pharmaceuticals 10.3.1.2 NB-001 - NanoBio Corporation 10.3.1.3 Orbactiv/ Nuvocid (oritavancin) - The Medicines Company 10.3.1.4 Luliconazole - Topica Pharmaceuticals 10.3.2 Drugs In Phase 2 Development For Skin Infections 10.3.3 Drugs In Phase 1 And Preclinical Pipeline For Skin Infections 10.4 Acne Drugs Development Pipeline, 2015 10.4.1 Drugs In Phase 3 Development For Acne 10.4.1.1 Duac low dose (clindamycin/ benzoyl peroxide) - GlaxoSmithKline 10.4.1.2 Visonac (photodynamic therapy) - Photocure 10.4.2 Drugs In Phase 2 Development For Acne 10.4.3 Drugs In Phase 1 And Pre-clinical Development For Acne 10.4.4 A Possible Vaccine For Acne 10.5 Dermatitis Drugs Development Pipeline, 2015 10.5.1 Drugs In Phase 3 Development For Dermatitis 10.5.1.1 Toctino (alitretinoin) - GSK 10.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher Pharmaceuticals 10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) - Pierre Fabre 10.5.1.4 REGN668/SAR231893 (dupilumab) - Regeneron/ Sanofi 10.5.1.5 Soriatane (acitretin) - InnovaDerm/Tribute Pharmaceuticals 10.5.2 Drugs In Phase 2 Development For Dermatitis 10.5.3 Drugs In Phase 1 And Preclinical Stages Of Development For Dermatitis 10.6 Other Dermatological Drugs Development Pipeline, 2015 10.6.1 Other Dermatological Drugs: Filed or Recently Launched 10.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall 10.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera 10.6.1.3 Keytruda (MK-3475, Pembrolizumab) - Merck 10.6.1.4 Mirvaso (brimonidine) - Galderma 10.6.1.5 Picato (ingenol mebutate) - LEO Pharma 10.6.1.6 Xolair (omalizumab) - Novartis/ Roche 10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2015 10.6.2.1 Atralin (tretinoin) - Valeant 10.6.2.2 BMS-936558 (nivolumab) - Bristol-Myers Squibb 10.6.2.3 CD5024 (ivermectin) - Galderma 10.6.2.4 Latisse (bimatoprost) – Allergan (Actavis) 10.6.2.5 LEE011, LGX818, and MEK162 - Novartis 10.6.2.6 Oleogel-S10 (triterpene extract) – Birken AG 10.6.2.7 PV-10 (Rose Bengal) - Provectus Pharmaceuticals 10.6.2.8 SR-T100 gel (Solanum incanum extract) - G&E Herbal Biotechnology 10.6.2.9 TVEC (talimogene laherparepvec) - Amgen 10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2015 10.6.4 Other Dermatological Drugs: Phase 1 and Preclinical Pipeline
11. Qualitative Analysis Of The Dermatological Drugs Market, 2015-2025 11.1 Market Factors Influencing Dermatological Drugs 11.2 SWOT Analysis Of The Global Dermatological Drugs Market, 2015-2025 11.2.1 Strengths 11.2.1.1 The High Unmet Clinical Need In Dermatology 11.2.1.2 A Healthy Pipeline Of Development-Stage Products 11.2.1.3 Strong Industry-Physician Relationships 11.2.2 Weaknesses 11.2.2.1 Limited Efficacy And Adverse Effects May Impact Product Uptake 11.2.2.2 Patient Adherence – A Major Challenge To Treatment Design 11.2.2.3 Impending Patent Expiries And The Challenges Posed By Generic Competition 11.2.3 Opportunities 11.2.3.1 The High-Growth Sectors In Dermatology 11.2.3.2 Personalised Dermatology: Technological Advances In Genomics 11.2.3.3 Advances In Topical Drug Delivery Methods Offers Product Differentiation 11.2.3.4 Consolidation Within Dermatology – Opportunity For Synergistic Growth? 11.2.4 Threats 11.2.4.1 Uncertain Surrounding Reimbursement And Payment Approvals 11.2.4.2 The Rising Cost Of Research And Development 11.2.4.3 Downward Pressures On Drug Prices 11.3 Porter’s Five Force Analysis Of The Global Dermatological Drugs Market, 2015-2025 11.3.1 Threat Of New Entrants 11.3.2 Threat Of Substitutes 11.3.3 Rivalry Among Competitors 11.3.4 Power Of Buyers 11.3.5 Power Of Suppliers
12. Expert Opinions from Our Primary Research 12.1 Interview With Kathleen Deardorff, Chief Operating Officer At Photocure ASA 12.1.1 Visonac As An Innovative First-In-Class Treatment 12.1.2 Photocure’s Development Plans For Visonac 12.1.3 Commercialisation Strategy For Visonac 12.1.4 On The Geographical Reach Of Acne Treatments 12.1.5 The Key Unmet Needs Within Patient Populations For Acne 12.1.6 The Key Forces Driving And Restraining The Development Of Acne Therapies 12.1.7 On The Current Development Pipeline For Acne Therapies 12.1.8 On Photocure’s Plans For Future Growth 12.1.9 Future Prospects For The Acne Treatments Market
13. Conclusions 13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025 13.2 Leading Sectors In Dermatological Drugs In 2014 13.3 Leading Regions In The Dermatological Drugs Market In 2014 13.4 Future Outlook For The Various Sectors Within The Dermatological Drugs Market, 2015-2025 13.5 What Does The Future Hold For Dermatological Drugs?
List of Tables Table 1.1 Global Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2014-2025 (Redacted Data) Table 2.1 Clinical Trial Phases, 2015 Table 3.1 The Global Dermatological Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2014 Table 3.2 The Global Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2014-2025 Table 3.3 The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2014-2019, 2019-2025, 2014-2025 Table 3.4 The Global Dermatological Drugs Market: Market Share (%) by Sector, 2014, 2019, 2025 Table 4.1 Top Drugs In The Psoriasis Drugs Market: Revenue ($m) and Market Shares (%), 2014 Table 4.2 Psoriasis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025 Table 4.3 The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025 Table 4.4 Humira: Historical Sales ($m, AGR%), 2010-2014 Table 4.5 Humira: AbbVie Sales Forecast ($m, AGR%, CAGR%), 2014-2025 Table 4.6 Stelara: Historical Sales ($m, AGR%), 2010-2014 Table 4.7 Stelara: Sales Forecast ($m, AGR%, CAGR%), 2014-2025 Table 4.8 Enbrel: Historical Sales ($m,bn Yen, AGR%) by Company, 2008-2014 Table 4.9 Enbrel: Sales Forecast ($m, AGR%, CAGR%), 2014-2025 Table 4.10 Remicade: Historical Sales ($m, bn Yen, AGR%), 2010-2014 Table 4.11 Remicade: Sales Forecast ($m, AGR%, CAGR%), 2014-2025 Table 4.12 Daivobet: Sales Forecast ($m, AGR%, CAGR%), 2014-2025 Table 4.13 Soriatane: Sales Forecast ($m, AGR%, CAGR%), 2014-2025 Table 4.14 Other Psoriasis Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025 Table 5.1 Top Drugs In The Skin Infection Drugs Market: Revenue ($m) and Market Share (%),Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025 Table 8.11 The German Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 8.12 The French Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025 Table 8.13 The French Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 8.14 The UK Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025 Table 8.15 The UK Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 8.16 The Italian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025 Table 8.17 The Italian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 8.18 The Spanish Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025 Table 8.19 The Spanish Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 8.20 The Japanese Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025 Table 8.21 The Japanese Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 8.22 The Chinese Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025 Table 8.23 The Chinese Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 8.24 The Indian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025 Table 8.25 The Indian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 8.26 The Brazilian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025 Table 8.27 The Brazilian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 8.28 The Russian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025 Table 8.29 The Russian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 8.30 The Mexican Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025 Table 8.31 The Mexican Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 8.32 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2025 Table 8.33 The Rest of the World Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025 Table 9.1 Galderma: Company Overview, 2013 And 2014 Table 9.2 Johnson & Johnson: Company Overview, 2014 Table 9.3 Johnson & Johnson: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025 Table 9.4 AbbVie: Company Overview, 2014 Table 9.5 AbbVie: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025 Table 9.6 GlaxoSmithKline: Company Overview, 2014 Table 9.7 GlaxoSmithKline: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025 Table 9.8 GlaxoSmithKline: Dermatological Drugs Pipeline, 2015 Table 9.9 Pfizer: Company Overview, 2014 Table 9.10 Pfizer: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025 Table 9.11 LEO Pharma: Company Overview, 2014 Table 9.12 LEO Pharma: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025 Table 10.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2015 Table 10.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2015 Table 10.3 Psoriasis Drugs Pipeline: Phase 1 and Pre-Clinical Drugs, 2015 Table 10.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2015 Table 10.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2015 Table 10.6 Acne Drugs Pipeline: Phase 3 Drugs, 2015 Table 10.7 Acne Drugs Pipeline: Phase 2 Drugs, 2015 Table 10.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2015 Table 10.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2015 Table 10.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2015 Table 10.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2015 Table 10.12 Other Dermatological Drugs Pipeline: Phase 2 Drugs, 2015 Table 10.13 Other Dermatological Drugs Pipeline: Phase 1 and Preclinical Drugs, 2015 Table 11.1 SWOT Analysis of the Global Dermatological Drugs Market, 2015-2025 Table 13.1 Global Dermatological Drugs: Market Forecast ($m, CAGR%), 2014, 2018, 2021, 2025 Table 13.2 The Global Dermatological Drugs Market: Market Size ($m) and Market Shares (%) by Sector, 2014 Table 13.3 The Global Dermatological Drugs Market: Market Forecast ($m) by Region, 2014, 2018, 2021, 2025 Table 13.4 The Global Dermatological Drugs Market: Market Forecast ($m) by Sector, 2014, 2018, 2021, 2025
List of Figures Figure 1.1 Global Dermatological Drugs Market: Market Sectors, 2015 Figure 1.2 Spanish Dermatological Drugs Market: Market Forecast ($m, AGR%) 2014-2025 (Altered Data) Figure 2.1 Anatomy of the Human Skin Figure 3.1 The Global Dermatological Drugs Market: Revenue ($m) by Sector, 2014 Figure 3.2 The Global Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 3.3 The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2014-2019 Figure 3.4 The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2019-2025 Figure 3.5 The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2014-2025 Figure 3.6 The Global Dermatological Drugs Market: Market Share (%) by Sector, 2014 Figure 3.7 The Global Dermatological Drugs Market: Market Share (%) by Sector, 2019 Figure 3.8 The Global Dermatological Drugs Market: Market Share (%) by Sector, 2025 Figure 4.1 Top Drugs In The Psoriasis Drugs Market: Revenue ($m), 2014 Figure 4.2 Psoriasis Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 4.3 The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2014 Figure 4.4 The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2019 Figure 4.5 The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2025 Figure 4.6 Humira: Historical Sales ($m, AGR%), 2010-2014 Figure 4.7 Humira: AbbVie Sales Forecast ($m, AGR%), 2014-2025 Figure 4.8 Stelara: Historical Sales ($m, AGR%), 2010-2014 Figure 4.9 Stelara: Sales Forecast ($m, AGR%), 2014-2025 Figure 4.10 Enbrel: Historical Sales ($m) by Company, 2008-2014 Figure 4.11 Enbrel: Sales Forecast ($m, AGR%), 2014-2025 Figure 4.12 Remicade: Historical Sales ($m, AGR%), 2010-2014 Figure 4.13 Remicade: Sales Forecast ($m, AGR%), 2014-2025 Figure 4.14 Daivobet: Sales Forecast ($m, AGR%), 2014-2025 Figure 4.15 Soriatane: Sales Forecast ($m, AGR%), 2014-2025 Figure 4.16 Other Psoriasis Drugs: Sales Forecast ($m, AGR%), 2014-2025 Figure 5.1 Top Drugs In The Skin Infection Drugs Market: Revenue ($m), 2014 Figure 5.2 Skin Infection Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 5.3 The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2014 Figure 5.4 The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2019 Figure 5.5 The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2025 Figure 5.6 Cubicin: Sales Forecast ($m, AGR%), 2014-2025 Figure 5.7 Zyvox: Historical Sales ($m, AGR%), 2010-2014 Figure 5.8 Zyvox: Sales Forecast ($m, AGR%), 2014-2025 Figure 5.9 Valtrex: Historical Sales ($m, AGR%), 2010-2014 Figure 5.10 Valtrex: Sales Forecast ($m, AGR%), 2014-2025 Figure 5.11 Canesten: Historical Sales ($m, AGR%), 2011-2014 Figure 5.12 Canesten: Sales Forecast ($m, AGR%), 2014-2025 Figure 5.13 Lamisil: Novartis Sales Forecast ($m, AGR%), 2014-2025 Figure 5.14 Bactroban: Historical Sales ($m, AGR%), 2010-2013 Figure 5.15 Bactroban: Sales Forecast ($m, AGR%), 2014-2025 Figure 5.16 Other Skin Infection Drugs: Sales Forecast ($m, AGR%), 2014-2025 Figure 6.1 Top Drugs In The Acne Drugs Market: Revenue ($m), 2014 Figure 6.2 Acne Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 6.3 The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2014 Figure 6.4 The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2019 Figure 6.5 The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2025 Figure 6.6 Solodyn (Valeant): Sales Forecast ($m, AGR%), 2014-2025 Figure 6.7 Epiduo (Galderma/ Nestlé): Sales Forecast ($m, AGR%), 2014-2025 Figure 6.8 Claravis (Teva): Sales Forecast ($m, AGR%), 2014-2025 Figure 6.9 Aczone (Allergan): Sales Forecast ($m, AGR%), 2014-2025 Figure 6.10 Differin (Galderma/ Nestlé): Sales Forecast ($m, AGR%), 2014-2025 Figure 6.11 Absorica/Epuris: Sales Forecast ($m, AGR%), 2014-2025 Figure 6.12 Ziana: Sales Forecast ($m, AGR%), 2014-2025 Figure 6.13 Doryx: Sales Forecast ($m, AGR%), 2014-2025 Figure 6.14 Other Acne Drugs: Sales Forecast ($m, AGR%), 2014-2025 Figure 7.1 Top Drugs In The Dermatitis Drugs Market: Revenue ($m), 2014 Figure 7.2 Dermatitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 7.3 The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2014 Figure 7.4 The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2019 Figure 7.5 The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2025 Figure 7.6 Bepanthen/Bepanthol: Sales Forecast ($m, AGR%), 2014-2025 Figure 7.7 Protopic: Sales Forecast ($m, AGR%), 2014-2025 Figure 7.8 Elidel: Sales Forecast ($m, AGR%), 2014-2025 Figure 7.9 Elocon: Sales Forecast ($m, AGR%), 2014-2025 Figure 7.10 Other Dermatitis Drugs: Sales Forecast ($m, AGR%), 2014-2025 Figure 8.1 The Global Dermatological Drugs Market: Market Size ($m) by Region, 2014 Figure 8.2 US, EU5, and Japan Dermatological Drugs Market: Market Forecast ($m), 2014-2025 Figure 8.3 Brazil, Russia, India, China, and Mexico Dermatological Drugs Market: Market Forecast ($m), 2014-2025 Figure 8.4 The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2014-2019 Figure 8.5 The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2019-2025 Figure 8.6 The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2014-2025 Figure 8.7 The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2014 Figure 8.8 The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2019 Figure 8.9 The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2025 Figure 8.10 US Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.11 The EU5 Dermatological Drugs Market: Revenue ($m) by Country, 2014 Figure 8.12 Germany, France, UK, Italy, and Spain Dermatological Drugs Market: Market Forecast ($m), 2014-2025 Figure 8.13 The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2014 Figure 8.14 The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2019 Figure 8.15 The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2025 Figure 8.16 The German Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.17 The French Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.18 The UK Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.19 The Italian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.20 The Spanish Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.21 The Japanese Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.22 The Chinese Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.23 The Indian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.24 The Brazilian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.25 The Russian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.26 The Mexican Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.27 The Rest of the World Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 9.1 Johnson & Johnson: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025 Figure 9.2 AbbVie: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025 Figure 9.3 GlaxoSmithKline: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025 Figure 9.4 Pfizer: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025 Figure 9.5 LEO Pharma: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025 Figure 11.1 Porter’s Five Force Analysis of the Dermatological Drugs Market, 2015 Figure 13.1 Global Dermatological Drugs: Market Forecast ($m), 2014, 2018, 2021, 2025 Figure 13.2 The Global Dermatological Drugs Market: Market Size ($m) by Sector, 2014 Figure 13.3 The Global Dermatological Drugs Market: Market Forecast ($m) by Region, 2014-2025 Figure 13.4 The Global Dermatological Drugs Market: Market Forecast ($m) by Sector, 2014, 2018, 2021, 2025
Abbott Laboratories AbbVie AbGenomics Actavis Actelion AET BioTech Affinium (DebioPharm Group) AiCuris Alembic Pharmaceuticals Alkem Laboratories Allergan Almirall Amgen Anacor Pharmaceuticals AndroScience Group AnGes M G Anterios Apeiron Biologics Ascend Therapeutics Astellas Pharma Astion Pharma AstraZeneca Asubio Pharma (Daiichi Sankyo) Atrix Laboratories Aurobindo Pharma Ausio Pharmaceuticals Barr Laboratories Basilea Pharmaceutica Bayer Boehringer Ingelheim Berg Pharma Bertek Pharmaceuticals Biocon Biofrontera Biogen Idec Biotest AG Biovail Laboratories BioXpress Therapeutics Birken AG Braintree Laboratories Bristol-Myers Squibb Cadila Healthcare Can-Fite Biopharma Cardinal Health Celgene Cellceutix Celltech Celltrion Celsus Therapeutics Cempra Cipher Pharmaceuticals Cipla Circassia CollaGenex Compañía Internacional de Comercio Convoy Therapeutics Cosmo Pharmaceuticals Creabilis Therapeutics Cubist Pharmaceuticals Cutanea Life Sciences DAVA Pharmaceuticals Delenex Therapeutics Dermira Inc Dow Pharmaceutical Sciences Dr Reddy’s Laboratories Durata Therapeutics Eisai Eli Lilly Elorac Foamix Fortuderm Forward Pharma Fougera Pharmaceuticals (Sandoz) Fujifilm Fujisawa Healthcare Furiex Pharmaceuticals G&E Herbal Biotechnology G&W Laboratories Galderma (Nestle) Gene Signal Genentech (Roche) Genpharm Genzyme (Sanofi) GlaxoSmithKline Glenmark Pharmaceuticals Grupo Imperial Hanwha Pharma Heritage Pharmaceuticals Hospira Idera Pharmaceuticals Immune Response BioPharma Inc Immunex Impax Laboratories Incyte Innovaderm Research Instituto Terapeutico Delta Ltda Intrepid Therapeutics Janssen Biotech Johnson & Johnson Kosei Kyowa Hakko Kirin L’Oreal Laboratorios Kendrick LEO Foundation LEO Pharma Lupin Pharmaceuticals Maruho Meda Pharma Medicis (Valeant) Medison Pharma Melinta Pharmaceuticals Merck & Co Mitsubishi Tanabe Pharma Moleculin MorphoSys Mycenax Biotech Mylan Nabriva Therapeutics NanoBio Corporation Nestle NovaBay Novartis OpthaliX Par Pharmaceutical Paratek Pharmaceuticals Peplin (LEO Pharma) Perrigo Pfizer Pharmacia (Pfizer) PharmaPraxis Photocure Pierre Fabre Pliva Hrvatska Precision Dermatology Provectus Biopharmaceuticals Q-Med Ranbaxy Regeneron Roche Rochester Drug Co-operative Roxane Laboratories S.A.P.I. de C.V. (CISCA) Samsung Bioepis Sandoz (Novartis) Sanofi Shape Pharmaceuticals Shionogi & Co Sidmak Laboratories Sol-Gel Technologies Stiefel Laboratories (GSK) Sun Pharmaceuticals Sunovion Pharmaceuticals Switch Biotech Taisho Pharmaceuticals Takeda Targanta Therapeutics Taro Pharmaceuticals Tecnofarma Telormedix Teva The Medicines Company Therapeutics Inc Theravance Tolmar Inc Topica Pharmaceuticals Trius Therapeutics UCB Pharma Valeant Pharmaceuticals Vatera Healthcare Partners VBL Therapeutics Vedara Therapeutics ViiV Healthcare (GSK) ViroBay Vitacilina Corporation of America (VitaCorp) Warner Chilcott (Actavis) Welichem Biotech Wolters Kluwer Wyeth (Pfizer) XBiotech XenoPort Xoma
Organisations Mentioned In The Report Brazilian Society of Dermatology British Association of Dermatologists Chinese Society of Dermatology European Medicines Agency (EMA) European Pharmaceutical Market Research Association (EPhMRA) Food and Drug Administration (FDA) [US] Health Canada National Development and Reform Commission (NDRC) [China] National Health Services (NHS) [UK] National Institute for Health and Care Excellence (NICE) [UK] National Institute of Allergy and Infectious Diseases (NIAID) [US] National Institutes of Health [US] National Pharmaceutical Pricing Authority (NPPA) [China] Pharmaceuticals and Medical Devices Agency (PMDA) [Japan] Servicio Sanitario Nazionale (SSN) [US] St. Luke’s-Roosevelt Hospital Center, New York [US] UK Medicines and Healthcare Products Regulatory Agency (MHRA) United States District Court for the District of New Jersey University of California, San Diego [US] University of Michigan [US] US Patent Office
Download sample pages
Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
